-90%

est. 2Y upside i

HealthcareAI & MLSeed

Simplifying complex illness care at scale

Rank

#2360

Sector

HealthTech, AI, Telemedicine

Est. Liquidity

~6Y

Data Quality

Data: Low

RTHM presents a high-risk, moderate-upside equity opportunity for a job seeker.

Last updated: February 25, 2026

Bull (10%)+400%

RTHM successfully scales its AI-powered platform for complex chronic conditions, achieving significant market penetration in Long COVID and ME/CFS. Strong clinical outcomes and data advantage lead to a successful Series B/C round, pushing valuation to $500M+ by 2028.

Base (55%)+50%

RTHM maintains steady growth in its niche, securing follow-on funding but facing challenges in broader market adoption and incumbent competition. Valuation reaches approximately $150M, providing moderate returns for early equity holders.

Bear (35%)-80%

The 'deadpooled' status proves accurate, or RTHM struggles with regulatory hurdles, intense incumbent competition, or insufficient patient acquisition. A down round or liquidation event results in a valuation of $20M or less, wiping out common stock value due to $26M in liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $26M in liquidation preferences. In an exit at or below $100M, common stock holders would receive value only after investors are paid $26M.

Dilution Risk

high

As a seed-stage company, RTHM will likely require several more funding rounds, leading to significant future dilution for current equity holders.

Secondary Liquidity

none

There are no active secondary markets or tender offers for a seed-stage company like RTHM.

Questions to Ask at the Interview

Strategic questions based on RTHM's data — designed to show you've done your homework.

  • 1

    “How do you reconcile the 'Deadpooled' status reported by Tracxn for Rthm, Inc. with the company's active operations and recent announcements on your website?”

  • 2

    “Given the significant incumbent threat from large healthcare systems and digital health platforms, what specific strategies is RTHM employing to maintain its competitive moat beyond specialization in neglected complex illnesses?”

  • 3

    “Could you provide more clarity on the company's funding history and current valuation, as there appears to be conflicting information across public data sources? What is the expected timeline for the next funding round and potential liquidity events for employees?”

Community

Valuation Sentiment

Our model estimates -90% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.